Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept-based calcineurin inhibitor-free immunosuppression after kidney transplant
2013-002090-21Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2014
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belatacept, everolimus, tacrolimus, mycophenolate mofetil and antithymocyte globulin rabbit in kidney allograft rejection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of clinically suspected biopsy-proven acute rejection at 6 months. Started Apr 2014; status: completed.
02
Drugs
belatacepteverolimustacrolimusmycophenolate mofetilantithymocyte globulin rabbit
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2013-002090-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002090-21.